JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. SCYX, a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida…Read More
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY247 at the 11th Congress on Trends in Medical Mycology TIMM October 2023 in Athens Greece SCYNEXIS NASDAQSCYX
